Articles tagged with Platelets
Researchers have discovered a new way to predict brain bleeds in unborn babies and newborns by analyzing platelet levels. The study found that babies are guaranteed to develop brain bleeds if their platelet count drops below 10%, while moderate levels may trigger the condition, but not extremely low levels.
Researchers at RCSI University of Medicine and Health Sciences have discovered that platelets can form a provisional fibronectin matrix, similar to fibroblasts, which has potential implications for maintaining blood clot integrity during vascular repair. This finding challenges existing paradigms in wound healing.
Researchers at MIT have performed a systematic study on how different-sized polymer nanoparticles circulate in the body and interact with platelets to stop bleeding. They found that intermediate-sized particles (150 nanometers) were the most effective, with less likelihood of accumulating in off-target sites.
A new study by Dr. Brian Stansfield and Dr. Jessica Gancar found a clear linear relationship between mortality and red blood cell transfusion volume in newborns on ECMO, with a 14% decrease in survival chances for every transfusion. The study suggests that reducing transfusion volumes may improve outcomes.
Researchers discovered that activation of two specific receptors on platelets leads to cerebral venous thrombosis. The receptors CLEC-2 and GPIIb/IIIa are involved in the development of the disease, which affects younger people more often than classic strokes.
A real-world study found that mechanical thrombectomy reduced post-stroke disability in nearly half of ischemic stroke patients. The study analyzed 1,000 adult patients and found that clot composition played a role in recovery outcomes.
Case Western Reserve University researchers create nanoparticles that generate a protein mesh to stabilize blood clots and reduce blood loss. The technology could help save lives by rapidly stabilizing clots to reduce blood loss from traumatic injuries.
Researchers at the University of Tokyo and University of Virginia developed a new diagnostic technology that can identify patients at risk of microvascular thrombosis. The technology analyzes blood samples to detect excessive platelet aggregation, an early indicator of blood clotting, in nearly 90% of COVID-19 patients.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
A new programme is seeking to understand the rare condition of blood clotting with low platelets in COVID-19 infection and vaccination. The vast majority of people experience mild reactions, but some develop severe side effects, including blood clots and low platelet levels.
A new test separates people into different groups based on their platelet response, potentially leading to more precise treatments for strokes and heart attacks. Researchers developed a computer software to analyze and classify data from human participants' blood samples.
Researchers have discovered a link between low platelet counts and brain bleeds in newborns, which can lead to fatal strokes or permanent neurological conditions. The study aims to develop new treatments to prevent these strokes.
A recent study published in Scientific Reports found that the degree of platelet reduction is more strongly linked to mortality risk in sepsis than absolute platelet count. The researchers also discovered that a significant decrease in platelet count increases the risks of bleeding and thrombosis development.
Researchers identify novel mechanism of formation of procoagulant platelets activated by S100 A8/A9 binding to the GPIbα receptor, a previously unknown target for anti-coagulant therapies. This discovery may lead to new treatments and prevention strategies for inflammatory and thrombotic diseases.
Researchers discovered that certain catalyst materials, such as erythrite, improve in performance over time due to restructuring. This process increases the surface area of the material, allowing for more reactions to occur, resulting in higher oxygen yields and doubled electrical current generation.
A study found that antibodies produced to fight Covid-19 can trigger platelet activity, leading to fatal blood clots. Researchers developed a lab-based test to replicate this process, and suggest that existing medications may be able to inhibit platelet response.
Researchers discovered the molecular mechanism behind vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but fatal blood clotting disorder. The findings will enable the development of rapid diagnostic tests and new strategies to prevent VITT, making vaccines safer.
Scientists at McMaster University have developed a new treatment approach for people suffering from VITT, combining anti-clotting drugs with high doses of intravenous immunoglobulin. The treatment's effectiveness was shown in three Canadian patients who received the AstraZeneca vaccine and developed VITT.
Researchers at Georgia Institute of Technology and Emory University have made a significant discovery in the physics of blood clotting. By modeling the dynamics of clot contraction, they found that platelets work best when not in total sync with each other, leading to a 90% decrease in clot volume.
Research led by Dr. Satya P. Kunapuli seeks to understand how platelets become activated to form clots that lead to cardiovascular diseases like stroke and heart attack. The study aims to identify molecular differences in platelet genes and proteins to facilitate the discovery of new signaling pathways relevant to cardiovascular disease.
Researchers at the University of Münster discovered that platelet-white blood cell interactions resolve lung inflammation by secreting anti-inflammatory substances and eliminating excess neutrophil granulocytes. This finding has implications for developing new therapy concepts to combat acute respiratory failure.
Scientists have created a miniature 3D bone marrow model that can predict patient responses to Eltrombopag therapy for platelet disorders. The model uses silk protein scaffolding and patient-derived cells to recreate human bone marrow conditions.
Researchers have identified a specific mechanism of von Willebrand Factor (vWF) that enables it to bind to platelets and initiate clotting. The discontinuous autoinhibitory module (AIM) is a prime site for new antithrombotic drug development.
Researchers found that duloxetine inhibited platelet function and protected against clot formation, potentially benefiting patients with both depression and cardiovascular disease. The study aims to develop new drugs based on the structure of duloxetine to protect from thrombosis.
A comparative study found that Heat not Burn products may cause reduced endothelial function and increased oxidative stress in users, similar to conventional cigarette smokers. The study suggests that these products should not be recommended for smoking cessation or as a less harmful alternative.
Researchers found that higher platelet counts linked to better outcomes for patients with staph sepsis, while repurposed drugs protect platelets and improve survival of septic mice. The study suggests that boosting the immune system by protecting platelets could reduce mortality in staph sepsis.
Two approved medications, ticagrelor and oseltamivir, protect platelets and improve survival in mice with S. aureus blood infections. These compounds could be repurposed to treat badly needed therapies for blood infections.
Researchers have found that platelets are the source of extracellular DNA in patients with lupus, leading to chronic inflammation. This discovery could lead to better understanding and treatment of the disease.
Researchers associate the enzyme LMWPTP with chemotherapy resistance, metastasis, and autoimmune diseases. Inhibiting this protein phosphatase could lead to novel monitoring and treatment opportunities for cancer and other diseases.
Two new posters will present investigative treatment options using NUWIQ and WILATE for rare bleeding disorders. The research focuses on long-term prophylaxis with Simoctocog Alfa for hemophilia A, as well as the use of a von Willebrand Factor/Coagulation Factor VIII Complex for treatment of inherited platelet disorders.
Researchers have identified six molecules that can be used as biomarkers to predict how severely ill a patient with COVID-19 will become. Additionally, they discovered a new mechanism causing life-threatening blood clots in COVID-19 patients and potential ways to treat them.
Tumors in ovarian cancer interact with platelets through broken blood vessel barriers, enabling metastasis. Organ-on-a-chip technology allows researchers to study this interaction and explore potential treatments.
Monash researchers have developed a drug that can prevent blood clots from forming, which are the primary cause of heart attacks and strokes. The drug has shown promising results in animal models and human cells, suggesting it could be a game-changer in cardiovascular disease treatment.
Researchers aim to reduce bleeding time for soldiers on the battlefield by developing synthetic platelet substitutes that can be easily transported and stored. The technology, which involves freeze-drying artificial platelets into a powder, could potentially address blood shortages and improve treatment outcomes in emergency situations.
Research found that COVID-19 causes platelets to become hyperactive, forming dangerous blood clots that can lead to cardiovascular problems. Understanding the underlying cause may lead to treatments to prevent this from happening in patients.
Researchers discovered that platelet-derived growth factor B (PDGFB) plays a key role in maintaining the vascular barrier in tumors, reducing the spread of cancer cells. In mouse models, PDGFB deletion from platelets led to increased circulating tumor cells and metastasis.
A University of Cincinnati cardiologist is conducting an observational study to understand why some patients undergoing transcatheter aortic valve replacement (TAVR) have better outcomes than others. The researcher aims to identify biomarkers that predict short- and long-term clinical outcomes and find ways to reduce bleeding risks.
A new study by the University of Bonn reveals that platelets exacerbate immune responses by activating inflammasomes and increasing IL-1 production. This finding has significant implications for treating autoimmune diseases such as rheumatism and diabetes.
A new tool using machine-learning technology distinguishes the cause of different types of blood clots based on subtle differences in their shape. The intelligent platelet aggregate classifier (iPAC) can help physicians diagnose and select treatments for patients with specific clot types.
Researchers at USF Health and Johns Hopkins Medicine developed a new treatment for necrotizing enterocolitis (NEC) by inhibiting the blood-clotting molecule thrombin with nanoparticles. The therapy, which was tested on newborn mice, showed promise in preventing NEC-like injury.
A new study led by University of Kentucky researcher Sidney Whiteheart aims to understand how platelets function in hemostasis and during immune responses. The research may lead to therapies to regulate platelet activation and lessen the risk of cardiovascular disease in patients with HIV1/AIDS or COVID-19.
A groundbreaking tool, LipidCreator, has been developed to efficiently analyze specific lipid groups and signal molecules, accelerating the discovery of biomarkers for diseases. This software enables scientists to quantify 60 lipid classes and their signaling molecules in larger studies than previously possible.
A team of researchers led by University of Delaware Professor Velia M. Fowler has made a groundbreaking discovery about MYH9-related disorders, a condition affecting 1 in 25,000 people. The study found that mutations in the MYH9 gene disrupt platelet formation and movement, leading to unstable clots and various health issues.
Researchers developed a nacre-inspired separator coating to improve lithium battery safety and impact resistance. The coating exhibits higher tensile strength, better electrolyte wettability, and smaller thermal shrinkage compared to commercial ceramic nanoparticle coatings.
Researchers have developed a method to target IL-1β blocking drugs to the heart after a heart attack, potentially reducing side effects. The approach uses platelet microparticles to deliver the drug directly to the damaged area, increasing concentration and promoting cardiac repair.
Researchers from Immanuel Kant Baltic Federal University used Raman spectroscopy to study the thrombocytes of patients with cardiovascular diseases and compared their spectra with those of healthy people. The study identified differences in spectral intensity that may indicate changes in physical characteristics of thrombocyte membranes.
After a stroke, sticky exosomes accumulate on the lining of blood vessels, activating platelets and causing them to adhere to the vessel walls. This buildup can lead to additional brain damage and worsen stroke outcomes. Synthetic exosomes may hold promise as potential treatment options.
Emerging methods aim to simulate the net-forming molecule behind clots, highlighting advances in understanding vWF behavior and potential therapies targeting platelet aggregation and ADAMTS13 enhancement. Researchers collaborate across biology and computer science to build an improved model for predicting thrombus formation.
Biomedical engineer Tara Deans receives $1.5 million grant to develop alternative platelets that can help stop tumor cells from spreading in the bloodstream. Her lab will engineer platelets with proteins that kill cancer cells, inspired by her friend's diagnosis with blood cancer.
Researchers at Thomas Jefferson University have discovered two gene variations that may modulate platelet cell behavior and affect the risk of developing cardiovascular disease. The study suggests that these genetic variants could be potential targets for modulating expression of CD36, a key regulator of platelet levels and activation.
Geriatric patients with ST segment elevation myocardial infarction who undergo primary percutaneous coronary intervention have higher in-hospital mortality rates if they have a high mean platelet volume. This is also associated with higher Gensini scores, creatinine concentrations, and lower HDL cholesterol levels.
Research by UCL and Yale University reveals that platelet cells were crucial for the evolution of eutherian mammals, including humans. The discovery suggests that these cells enabled haemochorial placentation, allowing mothers to prevent haemorrhaging at birth.
A team of Lehigh University researchers characterized the shear-induced extensional response of vWF, revealing new insights into the protein's biomechanical behavior. They also developed a coarse-grained model to explain the protein's flow-induced properties, shedding light on its role in blood clotting and platelet function.
A consortium of researchers from Portugal has developed a proof-of-concept experiment to produce a new blood-derived product by applying PEF to platelet concentrates. The process ensures the valorization of discarded components, providing a valuable source for cellular therapies and regenerative medicine.
A new experimental compound inhibits clot formation without raising the risk of bleeding, providing an effective and safer alternative to current therapies. The study found that the drug is well-tolerated at high doses and has a rapid, specific, and reversible action on platelets.
Researchers at the University of Sydney have used biomechanical engineering techniques to understand the mechanical forces that influence blood clotting. Their findings take them one step closer to developing new anti-thrombotic drugs without serious side effects.
Researchers developed PB2452, a monoclonal antibody fragment that reverses ticagrelor's antiplatelet effects within five minutes and sustains reversal for over 20 hours. The study found immediate and sustained reversal of ticagrelor's effects, with no serious adverse events or infusion reactions.
Researchers created a novel system to measure platelet function within two minutes, allowing doctors to estimate trauma patients' risk of bleeding. The device uses microfluidic technology and activates platelets with obstacle blocks, enabling real-time assessment of platelet forces.
A Michigan State University study found that fibrinogen accumulates in the remaining liver after surgery and triggers platelet activity to aid in regeneration. Low fibrinogen levels are associated with delayed regeneration and dysfunctional livers, making it a potential predictive marker for doctors.
A Marshall University researcher has been awarded a nearly $500,000 NIH grant to investigate the role of thymidine phosphorylase in thrombosis. The study aims to clarify the pathways mediating TYMP-enhanced platelet activation and establish pharmacological inhibition as a novel anti-thrombotic therapy.